Literature DB >> 22249974

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.

Hanna Lindberg1, Camilla Hofström, Mohamed Altai, Hadis Honorvar, Helena Wållberg, Anna Orlova, Stefan Ståhl, Torbjörn Gräslund, Vladimir Tolmachev.   

Abstract

Affibody molecules are a class of small (ca.7 kDa) robust scaffold proteins with high potential as tracers for radionuclide molecular imaging in vivo. Incorporation of a cysteine-containing peptide-based chelator at the C terminus provides an opportunity for stable labelling with the radionuclide (99m)Tc. The use of a GGGC chelator at the C terminus has provided the lowest renal radioactivity retention of the previously investigated peptide-based chelators. Previously, it has also been demonstrated that replacement of the His(6)-tag with the negatively charged histidine-glutamate-histidine-glutamate-histidine-glutamate (HEHEHE)-tag permits purification of affibody molecules by immobilized metal ion affinity chromatography (IMAC) and provides low hepatic accumulation of radioactivity of conjugates site-specifically labelled at the C terminus using several different nuclides. We hypothesized that the combination of a HEHEHE-tag at the N terminus and a GGGC chelator at the C terminus of an affibody molecule would be a favourable format permitting IMAC purification and providing low uptake in excretory organs. To investigate this hypothesis, a (HE)(3)-Z(HER2:342)-GGGC affibody molecule was generated. It could be efficiently purified by IMAC and stably labelled with (99m)Tc. (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC preserved specific binding to HER2-expressing cells. In NMRI mice, hepatic uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was lower than the uptake of the control affibody molecules, (99m)Tc-Z(HER2:2395)-VDC and (99m)Tc-Z(HER2:342)-GGGC. At 1 and 4 h after injection, the renal uptake of (99m)Tc-(HE)(3)-Z(HER2:342)-GGGC was 2-3-fold lower than uptake of (99m)Tc-Z(HER2:2395)-VDC, but it was substantially higher than uptake of (99m)Tc-Z(HER2:342)-GGGC. Further investigation indicated that a fraction of (99m)Tc was chelated by the HEHEHE-tag which caused a higher accumulation of radioactivity in the kidneys. Thus, a combination of a HEHEHE-tag and the GGGC chelator in targeting scaffold proteins was found to be undesirable in the case of (99m)Tc labelling due to a partial loss of site-specificity of nuclide chelation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249974     DOI: 10.1007/s13277-011-0305-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.

Authors:  Mohamed Altai; Helena Wållberg; Anna Orlova; Maria Rosestedt; Seyed Jalal Hosseinimehr; Vladimir Tolmachev; Stefan Ståhl
Journal:  Amino Acids       Date:  2011-05-15       Impact factor: 3.520

2.  Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.

Authors:  Sara Ahlgren; Kristofer Andersson; Vladimir Tolmachev
Journal:  Nucl Med Biol       Date:  2010-04-08       Impact factor: 2.408

3.  Radionuclide molecular imaging using Affibody molecules.

Authors:  Sara Ahlgren; Vladimir Tolmachev
Journal:  Curr Pharm Biotechnol       Date:  2010-09-01       Impact factor: 2.837

4.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

5.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Authors:  Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén-Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

7.  Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Authors:  Sara Ahlgren; Helena Wållberg; Thuy A Tran; Charles Widström; Magnus Hjertman; Lars Abrahmsén; Dietmar Berndorff; Ludger M Dinkelborg; John E Cyr; Joachim Feldwisch; Anna Orlova; Vladimir Tolmachev
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

8.  Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.

Authors:  Thuy A Tran; Torun Ekblad; Anna Orlova; Mattias Sandström; Joachim Feldwisch; Anders Wennborg; Lars Abrahmsén; Vladimir Tolmachev; Amelie Eriksson Karlström
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

9.  Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

Authors:  Helena Wållberg; Per-Ke Löfdahl; Kirsten Tschapalda; Mathias Uhlén; Vladimir Tolmachev; Per-Ke Nygren; Stefan Ståhl
Journal:  Protein Expr Purif       Date:  2010-10-26       Impact factor: 1.650

10.  Selection and characterization of Affibody ligands to the transcription factor c-Jun.

Authors:  Emma Lundberg; Hjalmar Brismar; Torbjörn Gräslund
Journal:  Biotechnol Appl Biochem       Date:  2009-01       Impact factor: 2.431

View more
  13 in total

1.  Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with 99mTc-Hynic-PEG-AE105.

Authors:  Xin Zhang; Y E Tian; Fangfang Sun; Hongbo Feng; Chun Yang; Xiaoyan Gong; Guang Tan
Journal:  Oncol Lett       Date:  2015-07-17       Impact factor: 2.967

Review 2.  Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Authors:  Xianwen Hu; Dandan Li; Yujie Fu; Jiashen Zheng; Zelong Feng; Jiong Cai; Pan Wang
Journal:  Front Oncol       Date:  2022-06-15       Impact factor: 5.738

3.  CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-25

4.  [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.

Authors:  Anna Orlova; Camilla Hofström; Joanna Strand; Zohreh Varasteh; Mattias Sandstrom; Karl Andersson; Vladimir Tolmachev; Torbjörn Gräslund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-21       Impact factor: 9.236

5.  Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.

Authors:  Bogdan Mitran; Mohamed Altai; Camilla Hofström; Hadis Honarvar; Mattias Sandström; Anna Orlova; Vladimir Tolmachev; Torbjörn Gräslund
Journal:  Amino Acids       Date:  2014-11-27       Impact factor: 3.520

6.  Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.

Authors:  Ken G Andersson; Maryam Oroujeni; Javad Garousi; Bogdan Mitran; Stefan Ståhl; Anna Orlova; John Löfblom; Vladimir Tolmachev
Journal:  Int J Oncol       Date:  2016-10-05       Impact factor: 5.650

7.  Optimal His-Tag Design for Efficient [99mTc(CO)3]+ and [188Re(CO)3]+ Labeling of Proteins for Molecular Imaging and Radionuclide Therapy by Analysis of Peptide Arrays.

Authors:  Jennifer D Williams; Florian Kampmeier; Adam Badar; Kevin Howland; Margaret S Cooper; Gregory E D Mullen; Philip J Blower
Journal:  Bioconjug Chem       Date:  2020-11-26       Impact factor: 4.774

8.  Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function.

Authors:  Seiji Shibasaki; Miki Karasaki; Torbjörn Gräslund; Per-Åke Nygren; Hajime Sano; Tsuyoshi Iwasaki
Journal:  AMB Express       Date:  2014-11-11       Impact factor: 3.298

9.  Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.

Authors:  Dominik Summer; Javad Garousi; Maryam Oroujeni; Bogdan Mitran; Ken G Andersson; Anzhelika Vorobyeva; John Löfblom; Anna Orlova; Vladimir Tolmachev; Clemens Decristoforo
Journal:  Mol Pharm       Date:  2017-12-01       Impact factor: 4.939

10.  Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.

Authors:  Javad Garousi; Sarah Lindbo; Bogdan Mitran; Jos Buijs; Anzhelika Vorobyeva; Anna Orlova; Vladimir Tolmachev; Sophia Hober
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.